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Introduction

Results

Conclusion

• Stimulant abuse is a rapidly growing epidemic both in
the US and globally
• High CV morbidity and mortality from associated
tachyarrhythmias, hypertension, MI, structural
changes, and disruption of coagulation homeostasis.
• Sympathetic overstimulation leads to direct free
radical oxidation, mitochondrial injury, apoptosis, and
metabolic derangements.
• LV heart failure (apical ballooning and hypokinesis)
leads to hemodynamic flow disturbances which
promote turbulent blood flow and stagnation.

• This patient was managed with carvedilol, lisinopril,
furosemide, and spironolactone with the addition of
rivaroxaban for the LV thrombus.
• Patient improved clinically and was discharged within
days; however, did not follow up outpatient and
presented with cardiogenic shock within 12 months.

Case Report

• Studies suggest the myocardial changes can be reversed with
cessation of methamphetamine abuse.

• 42-year-old male with history of polysubstance abuse
(opiates, amphetamines, marijuana, tobacco) who
presented with intermittent, sharp, non-exertional
chest pain radiating to the left shoulder x 5 months.
Assoc shortness of breath, symmetric bilateral lower
extremity, urine output, orthopnea, dyspnea on
exertion, and weight gain.
• PE: tachycardia, JVD, audible S3, and diffuse pitting
anasarca.
• Labs: BNP > 17,000
• CXR: significant cardiomegaly
• Chest CT with contrast: extensive bilateral pleural
effusions and atelectasis with a large thrombus.
• 2D-TTE: severely reduced left ventricular systolic
function with diffuse hypokinesis and a calculated left
ventricular ejection fraction (LVEF) of 28.1%. A fixed
apical echogenic mass measuring 2.1×1.8×1.8 cm
was identified.

Conclusion / Discussion
• We have reviewed the potential cardiac complications of
methamphetamine use, focusing on catecholamine-driven
dilated cardiomyopathy and associated thrombus formation.

Figure 1. Contrast CT scan of chest. A 2.4 cm opacity can be
seen within the apex of the left ventricle (LV) consistent with
thrombus formation. The LV thrombus can be seen in the sagittal
(A), coronal (B) and axial (C) views.

• No current guideline-driven recommendations for
methamphetamine user screening with 2D-TTE or for
prophylactic anticoagulation for patients with MACM.
• Encourage familiarity with these potential complications and
screen selected patients with symptoms or who are at higher
risk for complications.
• Emphasize the importance of obtaining a detailed social
history and providing patient education on potential
complications.
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